Core Insights - Dexcom's new CEO, Jake Leach, is focusing on international market growth as a key strategy for 2026 following strong FY25 revenues [1][4] - The company aims to leverage its US leadership in continuous glucose monitors (CGM) to expand access and coverage internationally [2][3] Financial Performance - Dexcom reported FY25 revenues of approximately $4.66 billion, representing a 16% increase from FY24 [4] - The company anticipates FY26 revenues could reach up to $5.25 billion [4] - Dexcom's market capitalization stands at $27.68 billion, with shares rising by 5.31% to $70.98 following the FY25 financial release [6] Market Position - In 2025, Dexcom held a 44.7% market share in the US CGM market, ranking second to Abbott, which had a 48.5% share [2] - Dexcom's market share in international regions such as Europe, APAC, and MEA is significantly lower compared to Abbott [2] Customer Growth - The company exited 2025 with approximately 3.5 million active customers, marking an increase of over 20% from 2024 [5] Future Developments - Dexcom plans to release randomized controlled trial results from a large non-insulin patient study in 2026, which is expected to support global expansion efforts [3] - The CGM market is projected to grow at a CAGR of 9.85%, reaching a valuation of $15.69 billion by 2035 [3] - The company is also working on the next-generation G8 CGM, although no launch timeline has been disclosed [7]

Group 1 - Abbott Laboratories (ABT) plans to acquire Exact Sciences (EXAS) in a deal valued at up to $23 billion, indicating a significant investment in the cancer detection sector [1] - Exact Sciences' shares surged 18% in premarket trading following the announcement, building on a previous 23.7% increase after reports of a potential deal [1] - Abbott's stock experienced a decline of 3%, closing at $126.15, reflecting market reactions to the acquisition news [1]

Group 1 - Exact Sciences (EXAS) stock surged 18.8% to $82.75 following a Bloomberg report indicating that Abbott Laboratories (ABT) is nearing a deal to acquire the cancer-detection company [1] - Abbott Laboratories' stock declined by 3.9% to $124.97 amid the news of the potential acquisition [1] - The increase in Exact Sciences' stock price has pushed it into a breakout, surpassing a buy point of $72.83 from a cup base [1] Group 2 - Insulet was highlighted as the IBD Stock of the Day, experiencing a significant post-earnings reaction and currently in a consolidation phase [2] - Exact Sciences demonstrated market leadership with a jump to an 83 RS rating, indicating strong relative strength in the market [4] - Abbott Laboratories faced a mixed report, although one segment showed positive performance [4]

Financial Data and Key Metrics Changes - In Q3 2025, net revenue grew by 90% to $8.1 million compared to $4.3 million in the prior year period, driven by Eversense 365 US revenue of $6.4 million and $1.7 million from outside the US [17][20][24] - Gross profit was $3.5 million, an increase of $7.5 million from the prior year, primarily due to improved margins on 365-day product sales [18][19] - Net loss decreased to $19.5 million, or $0.43 loss per share, compared to a net loss of $24 million, or $0.77 loss per share in Q3 2024 [20] Business Line Data and Key Metrics Changes - Revenue growth was driven by a 160% increase in new patient shipments year-over-year, with new insertions increasing nearly 150% year-over-year [5][6] - Approximately 60% of new patients in Q3 originated from direct-to-consumer (DTC) advertising, with 40% from healthcare provider (HCP) referrals [6][8] - The number of providers actively prescribing Eversense grew by more than 55% year-over-year, with 75 new trained inserters added, representing a 140% increase from the same time last year [8][9] Market Data and Key Metrics Changes - The installed base of Eversense grew over 150% year-over-year and nearly 40% sequentially, reflecting accelerating adoption among patients and providers [6][8] - The DTC campaign led to a 300% increase in patient leads year-over-year and an 85% increase sequentially [5][6] - The company anticipates that the transition from Ascensia will allow it to recognize 100% of revenues, which is expected to positively impact future revenue growth [18][20] Company Strategy and Development Direction - The company executed a memorandum of understanding with Ascensia Diabetes Care to reassume control of Eversense commercialization, allowing for greater control over strategy and investments [4][10] - The company plans to continue investing in DTC marketing, primarily through social media, to drive demand and awareness [6][8] - Future product development includes the anticipated CE Mark approval for Eversense 365 in Europe, expected before the end of 2025, and the launch planned for the first half of 2026 [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing significant new patient additions and top-line growth due to expanding awareness and adoption of Eversense 365 [25][26] - The company expects full-year 2025 global net revenue to be approximately $35 million, with a strong Q4 anticipated due to new patient starts and reorders from first US 365 patients [20][22] - Management highlighted margin improvements, projecting gross profit margins to grow to roughly 50% in 2026 and approximately 70% at scale [14][23] Other Important Information - The company is focused on expanding access to its unique system and advancing technology to simplify glucose testing for people with diabetes [14][25] - The transition to resume control of Eversense commercialization is progressing well, with nearly all employees from Ascensia's US CGM business electing to join Senseonics [11][12] Q&A Session Summary Question: Follow-up on growth opportunities in DTC - Management noted a significant increase in switchers from existing CGM systems, with 90% of new patients coming from this group, primarily from Dexcom and Libre [30][31] Question: Integration with Twist insulin delivery system - The first patients are expected to start in early Q1 2026, with a ramp-up anticipated later in the year [32][34] Question: Update on inserter network evolution and reimbursement - The EonCare model is expanding, with a focus on primary care and Medicare patients, and the company is seeing growth in providers interested in institutionalizing the insertion process [38][40] Question: Update on private payers and bundled payment reimbursement - Management expects continued transitions among private payers, with significant progress made in the first half of the year [42][44] Question: Details on DTC marketing spend and its effectiveness - Increased DTC spending has shown a direct correlation with patient acquisition, though there is a need for education and conversion [62][63] Question: Revenue guidance and inventory dynamics for 2026 - The company anticipates some inventory dynamics affecting revenue recognition in 2026, but remains on track for patient growth [55][66]

Core Viewpoint - Phil Mickelson has denied allegations of insider trading related to Sable Offshore Corp, claiming the accusations are unfounded and suggesting they may be an attempt at stock manipulation [1][2]. Group 1: Allegations and Responses - Hunterbrook Media published a report alleging that Sable Offshore's CEO, Jim Flores, disclosed non-public information about the company needing to raise up to $200 million by the end of 2025 to select investors [2]. - Mickelson is accused of sharing this non-public information after a conversation with Flores, which he vehemently denies, stating he makes no trades and is extremely cautious [2][3]. - In a post on X, Mickelson characterized the allegations as slanderous and suggested that the publication itself may be engaging in stock manipulation [2]. Group 2: Legal Implications - If the allegations against Mickelson are proven true, he could face serious legal consequences, marking another instance of his involvement with insider trading claims [3]. - Mickelson previously settled a case with the SEC in 2016 related to insider trading, paying over $1 million, although he was not formally charged [3].

Core Viewpoint - Dexcom shares fell 12% in premarket trading due to executives indicating that the company's 2026 growth forecast may not meet Wall Street expectations [1] Company Summary - Dexcom is a medical device maker that specializes in continuous glucose monitoring systems [1] - The decline in share price reflects investor concerns regarding future growth potential [1] Industry Summary - The medical device industry is facing scrutiny as companies adjust growth forecasts amid changing market conditions [1] - Investor sentiment in the sector may be influenced by individual company performance and guidance [1]

Core Insights - Dexcom reported Q3 revenue of $1.21 billion, representing a 22% year-over-year increase, with net income rising to $283.8 million from $134.6 million in Q3 2024 [1][2] Financial Performance - Q3 revenue: $1.21 billion [1] - Year-over-year revenue increase: 22% [1] - Net income: $283.8 million, up from $134.6 million in Q3 2024 [1] Product Issues and Resolutions - Dexcom faced quality issues with its G7 continuous glucose monitors (CGMs) earlier in the year, specifically related to deployment failures [4] - The company has addressed these issues and expects a reduction in device complaints moving forward [3][4] - Improvements have been made to Bluetooth connectivity and adhesive quality of the CGMs [4] Customer Feedback and Market Impact - Executives reported stable complaint rates for the G7 devices, with ongoing efforts to enhance customer service [3][6] - There was a noted impact on new patient starts due to earlier product issues, but the company continues to see "hundreds of thousands" of new customer starts [6] - Feedback from prescribers indicates significant improvements in product performance after addressing initial challenges [5]

Core Insights - ŌURA has raised over $900 million in funding, primarily for the growth of its health technology offerings, with a valuation estimated at $11 billion [1][2] - The company reported revenues exceeding $500 million last year, doubling from the previous year, and aims to double its revenue again by 2025, potentially surpassing $1 billion in annual sales [2] - ŌURA is focusing on advancements in AI, product refinement, and international distribution expansion [2][4] Company Developments - CEO Tom Hale emphasized the funding as a testament to ŌURA's business strength and the trust of its members, aiming to promote proactive health [3] - The company announced a leadership transition, appointing David Shuman as the new board chair, succeeding Eurie Kim [4][5] - ŌURA is expanding its product line with new offerings, including the Oura Ring 4 Ceramic and Health Panels for lab test management [5] Market Expansion - In a strategic move, ŌURA plans to enter the consumer diabetes market with a new glucose monitoring feature for its ring, utilizing data from Dexcom's continuous glucose monitor [6]

Core Insights - Garmin has announced partnerships with Brooks, Dexcom, Maurten, Shokz, and Therabody to enhance the Garmin Marathon Series, starting with races in Toledo, Ohio on September 21, 2025 [1][8] Company Contributions - **Brooks**: Provides performance running footwear and apparel, offering participants a branded running shirt and showcasing gear at the expo [3] - **Dexcom**: Offers innovative glucose biosensing technology, including the Dexcom G7 and Stelo, to help runners track glucose levels, with a presence at the expo and finish line festival [4] - **Maurten**: Known for sports nutrition, will supply gels at aid stations to support runners during the event, and will also be present at the expo [5] - **Shokz**: Specializes in open-ear listening technology, will showcase headphones at the expo and provide support at cheer stations during the race [6] - **Therabody**: Focuses on recovery devices to enhance athletic performance, offering exclusive deals and recovery zones throughout the event [7] Event Details - The Garmin Marathon Series will feature events in Toledo, Ohio, and Tucson, Arizona, with four race distances: a full marathon, half marathon, 10K, and 5K, with registration currently open [8]

The transaction, once completed, will result in WORIO becoming a wholly owned subsidiary of OSR Holdings Co., Ltd. ("OSRK"), a Korean affiliate of OSRH. As previously disclosed, WORIO shareholders will receive newly issued OSRK shares, along with a conditional right to exchange those shares for OSRH common stock if OSRH's share price reaches $10.00 or more within three years from the signing of the Term Sheet. WORIO Shareholders Align with OSRH Upside The company emphasizes that the $10 OSRH share condition ...